Nurix Therapeutics, Inc. (NRIX) reported a first quarter net loss of $87.2 million or $0.79 per share compared with a net loss of $56.4 million or $0.67 per share, prior year. Revenue was $6.3 million compared with $18.5 million, a year ago. The company said revenue from the collaboration with Sanofi decreased as the initial research term for certain drug targets ended.
Cash, cash equivalents and marketable securitieswere $540.7 million as of February 28, 2026.
In pre-market trading on NasdaqGM, Nurix shares are down 3.06 percent to $15.85.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.